<DOC>
	<DOCNO>NCT00197184</DOCNO>
	<brief_summary>To evaluate persistence anti-hepatitis A virus ( HAV ) anti-hepatitis B surface antigen ( HBs ) antibodies 2 , 3 , 4 5 year administration first dose study vaccine . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Long Term Follow-up Study Years 2 , 3 , 4 5 Where 2 Dosing Schedules Combined Hepatitis A B Vaccine Were Compared</brief_title>
	<detailed_description>Open , randomise , self-contained , multicentric , multinational , long-term antibody persistence study . Immune persistence compare subject receive either two dose three dos GSK Biologicals combine hepatitis A hepatitis B vaccine . The long-term follow-up study involve take blood sample approximately 2 , 3 , 4 5 year primary vaccination combine hepatitis A B vaccine ass antibody persistence . No additional subject recruit long term follow-up period .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Participation primary study Written inform consent obtain long term follow visit .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>13 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Combined hepatitis A B vaccine</keyword>
	<keyword>Twinrixâ„¢</keyword>
</DOC>